会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 5. 发明授权
    • Process for the preparation of 5-(2-amino-pyrimidin-4-yl)-2-aryl-1H-pyrrole-3-carboxamides
    • 制备5-(2-氨基 - 嘧啶-4-基)-2-芳基-1H-吡咯-3-甲酰胺的方法
    • US08399668B2
    • 2013-03-19
    • US12989518
    • 2009-04-30
    • Matteo D'AnelloCarlo BattistiniMaria Gioia FornarettoErmes Vanotti
    • Matteo D'AnelloCarlo BattistiniMaria Gioia FornarettoErmes Vanotti
    • C07D403/04
    • C07D403/04
    • The present invention relates to a process for the preparation of 5-(2-amino-pyrimidin-4-yl)-2-aryl-1H-pyrrole-3-carboxamides and to the useful intermediate compounds of such process. 5-(2-Amino-pyrimidin-4-yl)-2-aryl-1H-pyrrole-3-carboxamides are described and claimed in WO2007110344, which also discloses processes for their preparation. These compounds can be advantageously prepared through a process which allows to obtain the desired products in high yields and purity and with a limited number of steps. The synthesis is starting from a cyano pyrrole derivative, and is characterized from the final hydrolysis of 5-(2-amino-pyrimidin-4-yl)-2-aryl-1H-pyrrole-3-carbonitrile. The compounds prepared according to the process of the present invention are endowed with protein kinase inhibiting activity and, more particularly, Cdc7 or Cdc7/Cdks inhibiting activity. The compounds are therefore useful in the treatment of a variety of cancers, cell proliferative disorders and diseases associated with protein kinases.
    • 本发明涉及制备5-(2-氨基 - 嘧啶-4-基)-2-芳基-1H-吡咯-3-甲酰胺的方法和该方法的有用的中间体化合物。 在WO2007110344中描述和要求保护5-(2-氨基 - 嘧啶-4-基)-2-芳基-1H-吡咯-3-甲酰胺,其也公开了其制备方法。 这些化合物可以有利地通过允许以高产率和纯度以及有限数量的步骤获得所需产物的方法制备。 合成起始于氰基吡咯衍生物,其特征在于5-(2-氨基 - 嘧啶-4-基)-2-芳基-1H-吡咯-3-甲腈的最终水解。 根据本发明的方法制备的化合物具有蛋白激酶抑制活性,更具体地,赋予Cdc7或Cdc7 / Cdks抑制活性。 因此,这些化合物可用于治疗多种癌症,细胞增殖性疾病和与蛋白激酶相关的疾病。
    • 7. 发明授权
    • The process for preparing 6-deoxynthracyclines
    • 6-脱氧蒽环的制备方法
    • US4939282A
    • 1990-07-03
    • US622177
    • 1984-06-19
    • Francesco AngelucciSergio PencoErmes VanottiFederico Arcamone
    • Francesco AngelucciSergio PencoErmes VanottiFederico Arcamone
    • C07C50/38A61K31/70A61K31/7028A61K31/7034A61K31/704A61P35/00C07C45/00C07C46/00C07C50/36C07C67/00C07D407/04C07H15/252
    • C07D407/04C07H15/252
    • A new process for the preparation of 6-deoxyanthracyclinones of general formula I: ##STR1## wherein R represents a hydrogen atom, a hydroxy group or a lower alkoxy group is described. The process provides a total synthesis of the 6-deoxyanthracyclinones of formula I using 1,2,3,6-tetrahydro-phthalate as starting material. The obtained racemic mixture of the compounds of formula I, if desired, can be submitted to optical resolution by the conventional method of conversion to diastereomeric derivatives using a chiral resolving agent. Alternatively, the racemic mixture can be used as such for the condensation with a suitably protected halosugar derivative to obtain alpha glycosidic derivatives of formula XV: ##STR2## wherein R.sub.1 represents a hydrogen atom or a hydroxy group, one of R.sub.2 and R.sub.3 represents a hydrogen atom, the other of R.sub.2 and R.sub.3 represents a hydrogen atom or a hydroxy group and X is a hydrogen atom or a trifluoro acetyl group. The N-trifluoroacetyl 7S:9S and 7R:9R derivatives of the .alpha.-glycosides of formula XV can be separated by chromatography on silica gel to obtain, after mild alkaline hydrolisis the wanted 7S:9S .alpha.-glycosides (R.sub.1 =H) as free bases and can eventually be transformed into their corresponding doxorubicin derivatives (R.sub.1 =OH) by known procedures.
    • 描述了制备通式I的6-脱氧尿嘧啶的新方法:其中R表示氢原子,羟基或低级烷氧基。 该方法提供使用1,2,3,6-四氢邻苯二甲酸酯作为起始原料的式I的6-脱氧蒽环类的全合成。 如果需要,所得到的式I化合物的外消旋混合物可以通过使用手性拆分剂转化成非对映体衍生物的常规方法进行光学拆分。 或者,外消旋混合物可以直接用于与适当保护的卤糖衍生物的缩合,以获得式XV的α糖苷衍生物:其中R 1表示氢原子或羟基,R 2和R 3之一表示 氢原子,R2和R3中的另一个表示氢原子或羟基,X是氢原子或三氟乙酰基。 式XV的α-糖苷类的N-三氟乙酰基7S:9S和7R:9R衍生物可以通过硅胶色谱分离,得到在温和的碱性水解后,所需的7S:9Sα-糖苷(R1 = H)为游离 碱,并且最终可以通过已知的方法转化成它们相应的多柔比星衍生物(R1 = OH)。